Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china
10.2147/CMAR.S219722
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Published: |
Dove Medical Press Ltd
2021
|
| Subjects: | |
| Online Access: | https://scholarbank.nus.edu.sg/handle/10635/210062 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | National University of Singapore |
| id |
sg-nus-scholar.10635-210062 |
|---|---|
| record_format |
dspace |
| spelling |
sg-nus-scholar.10635-2100622023-08-30T22:11:29Z Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china You, R. Liu, J. Wu, D.B.-C. Qian, X. Lyu, B. Zhang, Y. Luo, N. SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH Afatinib Economic analysis EGER mutation testing Incremental cost-effectiveness ratio NSCLC 10.2147/CMAR.S219722 Cancer Management and Research 11 10239-10248 2021-12-09T04:58:05Z 2021-12-09T04:58:05Z 2019 Article You, R., Liu, J., Wu, D.B.-C., Qian, X., Lyu, B., Zhang, Y., Luo, N. (2019). Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china. Cancer Management and Research 11 : 10239-10248. ScholarBank@NUS Repository. https://doi.org/10.2147/CMAR.S219722 1179-1322 https://scholarbank.nus.edu.sg/handle/10635/210062 Attribution-NonCommercial 4.0 International https://creativecommons.org/licenses/by-nc/4.0/ Dove Medical Press Ltd Scopus OA2019 |
| institution |
National University of Singapore |
| building |
NUS Library |
| continent |
Asia |
| country |
Singapore Singapore |
| content_provider |
NUS Library |
| collection |
ScholarBank@NUS |
| topic |
Afatinib Economic analysis EGER mutation testing Incremental cost-effectiveness ratio NSCLC |
| spellingShingle |
Afatinib Economic analysis EGER mutation testing Incremental cost-effectiveness ratio NSCLC You, R. Liu, J. Wu, D.B.-C. Qian, X. Lyu, B. Zhang, Y. Luo, N. Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china |
| description |
10.2147/CMAR.S219722 |
| author2 |
SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH |
| author_facet |
SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH You, R. Liu, J. Wu, D.B.-C. Qian, X. Lyu, B. Zhang, Y. Luo, N. |
| format |
Article |
| author |
You, R. Liu, J. Wu, D.B.-C. Qian, X. Lyu, B. Zhang, Y. Luo, N. |
| author_sort |
You, R. |
| title |
Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china |
| title_short |
Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china |
| title_full |
Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china |
| title_fullStr |
Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china |
| title_full_unstemmed |
Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china |
| title_sort |
cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china |
| publisher |
Dove Medical Press Ltd |
| publishDate |
2021 |
| url |
https://scholarbank.nus.edu.sg/handle/10635/210062 |
| _version_ |
1779154445517455360 |